-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche wins FDA approval for expanded use of HER2 companion tests in metastatic gastroesophageal adenocarcinoma

PUBT·08/26/2026 18:53:09
Listen to the news
Roche wins FDA approval for expanded use of HER2 companion tests in metastatic gastroesophageal adenocarcinoma
  • Roche won FDA clearance to expand PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH as companion diagnostics in metastatic gastroesophageal adenocarcinoma.
  • Tests identify HER2-positive patients eligible for Jazz Pharmaceuticals’ ZIIHERA in gastric, gastroesophageal junction, or esophageal adenocarcinoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608261452PR_NEWS_USPR_____SF34513) on August 26, 2026, and is solely responsible for the information contained therein.